Company Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.
Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.
Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.
The company was founded in 1781 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1781 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 49,281 |
| CEO | Christophe Weber |
Contact Details
Address: 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo, 103-8668 Japan | |
| Phone | 81 3 3278-2111 |
| Website | takeda.com |
Stock Details
| Ticker Symbol | TAK |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| CIK Code | 0001395064 |
| CUSIP Number | 874060205 |
| ISIN Number | US8740602052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christophe Weber | President, Chief Executive Officer and Representative Director |
| Dr. Seigo Izumo | Chair of Management Board |
| Milano Furuta | Chief Financial Officer and Director |
| Haruhiko Hirate | Member of Management Board |
| Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of Research & Development Global Science and Biomedical Policy |
| Norimasa Takeda | Chief Accounting Officer and Corporate Controller |
| Iwaaki Taniguchi | Senior Vice President of Corporate Finance and Controlling Department |
| Gabriele Ricci | Chief Data and Technology Officer |
| Christopher David O'Reilly | Global Head of Investor Relations and Global Finance |
| Yoshihiro Nakagawa | Global General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 6-K | Report of foreign issuer |
| Dec 13, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Sep 26, 2024 | 6-K | Report of foreign issuer |
| Aug 22, 2024 | 144 | Filing |
| Jul 31, 2024 | 6-K | Report of foreign issuer |
| Jul 10, 2024 | 144 | Filing |